Surf Wiki
Save to docs
general/amino-acid-derivatives

From Surf Wiki (app.surf) — the open knowledge base

Carglumic acid

Chemical compound

Chemical compound

FieldValue
Verifiedfieldschanged
verifiedrevid460019355
imageCarglumic acid.svg
image_classskin-invert-image
tradenameCarbaglu, Ucedane
Drugs.com
DailyMedIDCarglumic acid
pregnancy_AUB1
routes_of_administrationBy mouth
ATC_prefixA16
ATC_suffixAA05
legal_AUS4
legal_AU_comment
legal_BR
legal_CARx-only
legal_CA_comment
legal_DE
legal_NZ
legal_UK
legal_USRx-only
legal_US_comment
legal_EURx-only
legal_EU_comment
legal_UN
legal_status
bioavailability30%
protein_boundUndetermined
metabolismPartial
elimination_half-life4.3 to 9.5 hours
excretionFecal (60%) and kidney (9%, unchanged)
CAS_number_Ref
CAS_number1188-38-1
PubChem121396
IUPHAR_ligand7458
DrugBank_Ref
DrugBankDB06775
ChemSpiderID_Ref
ChemSpiderID1265942
ChemSpiderID2_Ref
ChemSpiderID2108351
UNII_Ref
UNII5L0HB4V1EW
KEGG_Ref
KEGGD07130
ChEBI_Ref
ChEBI71028
ChEMBL_Ref
ChEMBL1201780
synonyms(S)-2-ureidopentanedioic acid
IUPAC_name(2S)-2-(carbamoylamino)pentanedioic acid
C6H=10N=2O=5
SMILESC(CC(=O)O)C@@HNC(=O)N
StdInChI_Ref
StdInChI1S/C6H10N2O5/c7-6(13)8-3(5(11)12)1-2-4(9)10/h3H,1-2H2,(H,9,10)(H,11,12)(H3,7,8,13)/t3-/m0/s1
StdInChIKey_Ref
StdInChIKeyLCQLHJZYVOQKHU-VKHMYHEASA-N

| Drugs.com =

| elimination_half-life = 4.3 to 9.5 hours

Carglumic acid, sold under the brand name Carbaglu among others, is used for the treatment of hyperammonaemia. Carglumic acid is a carbamoyl phosphate synthetase 1 (CPS 1) activator.

The most common adverse effects include vomiting, abdominal pain, pyrexia (fever), and tonsillitis, anemia, diarrhea, ear infection, other infections, nasopharyngitis, decreased hemoglobin levels, and headache.

It was approved for medical use in the United States in March 2010. Carglumic acid is an orphan drug. It is available as a generic medication.

Medical uses

Carglumic acid is indicated for the treatment of acute hyperammonemia and chronic hyperammonemia.

References

References

  1. (21 June 2022). "Prescription medicines: registration of new chemical entities in Australia, 2015".
  2. (4 May 2016). "Health Canada New Drug Authorizations: 2015 Highlights".
  3. "Carbaglu- carglumic acid tablet".
  4. (17 September 2018). "Carbaglu EPAR".
  5. (17 September 2018). "Ucedane EPAR".
  6. (2004). "Restoration of ureagenesis in N-acetylglutamate synthase deficiency by N-carbamylglutamate". J Pediatr.
  7. (2002). "N-acetylglutamate synthase deficiency and the treatment of hyperammonemic encephalopathy". Ann Neurol.
  8. (16 February 2010). "Drug Approval Package: Carbaglu (Carglumic Acid) Tablets".
  9. (17 June 2014). "Carglumic acid Orphan Drug Designations and Approvals".
  10. (20 January 1998). "Carglumic acid Orphan Drug Designations and Approvals".
  11. (29 June 2023). "Competitive Generic Therapy Approvals".
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

amino-acid-derivatives carbamates glutamic-acids orphan-drugs
Want to explore this topic further?

Ask Mako anything about Carglumic acid — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report